Frontiers in Immunology · 2021 · 40 citations · 34 references
Veterinary MedicineImmunologyPathobiologyAutoimmunityClinical ImmunologyInflammationCytokine BiologyImmune Complex DiseaseInflammatory BiomarkersInflammatory Cell ResponsesInterferon ResponsesSystemic Lupus ErythematosusBiomarkersChemokine ResponsesInterferon Pathway GenesSystemic Lupus Erythematosus AssociationsType I Interferon BiomarkersType I Interferon PathwaysType I Interferon Signature
Objectives: Type I interferons (IFNs) are central and reflective of disease activity in systemic lupus erythematosus (SLE). However, IFN-α levels are notoriously difficult to measure and the type I IFN gene signature (IGS) is not yet available in clinical routine. This study evaluates galectin-9 and an array of chemokines/cytokines in their potential as surrogate markers of type I IFN and/or SLE disease activity. Methods: =21) was longitudinally followed. Chemokine/cytokine responses in immune complex triggered IFN-α activity was studied in healthy donor peripheral blood mononuclear cells (PBMC). Levels of chemokines/cytokines and galectin-9 were measured by immunoassays. Gene expression was quantified by qPCR. Results: The IGS was significantly (p<0.01) correlated with galectin-9 (rho=0.54) and CXCL10 (rho=0.37) levels whereas serum IFN-α correlated with galectin-9 (rho=0.36), CXCL10 (rho=0.39), CCL19 (rho=0.26) and CCL2 (rho=0.19). The strongest correlation was observed between galectin-9 and TNF (rho=0.56). IFN-α and disease activity (SLEDAI-2K) were correlated (rho=0.20) at cross-sectional analysis, but no significant associations were found between SLEDAI-2K and galectin-9 or chemokines. Several inflammatory mediators increased at disease exacerbation although CCL19, CXCL11, CXCL10, IL-10 and IL-1 receptor antagonist were most pronounced. Immune complex-stimulation of PBMC increased the production of CCL2, CXCL8 and TNF. Conclusion: Galectin-9 and CXCL10 were associated with type I IFN in SLE but correlated stronger with TNF. None of the investigated biomarkers showed a convincing association with disease activity, although CXCL10 and CCL19 performed best in this regard.
34
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan, Alan S. Cohen, James F. Fries et al. · Arthritis & Rheumatism · 1982 · 14.6K citations
Michelle Petri, Ana‐Maria Orbai, Graciela S. Alarcón et al. · Arthritis & Rheumatism · 2012 · 5.3K citations · Full text
Life Sciences, Immunology, Clinical Classification Systems +11
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text